Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  What’s our plan? It takes three steps:  --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine.  Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

SAN FRANCISCO , Oct. 25, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Invitae to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

– First genetics testing company to sit on Forum –  – Genetics perspective on committee will accelerate healthcare quality standards aligning with medical and technological advancements – SAN FRANCISCO , Sept. 27, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the company has received a three-year appointment to a National Quality Forum (NQF) committee that provides input on recommendations for quality standards that impact how healthcare is delivered.

Invitae Appointed to National Quality Forum Committee on Quality Standards for Healthcare

Broad market movements, unprofitability, and high short interest seem to be hitting Invitae stock this week.

Why Invitae Corporation Sank as Much as 25.5% This Week

NVTA's business model remains untested, having spent the past decade building a precarious market position with artificially low pricing strategies. Under its turnaround plan, management cut a third of the workforce, which bodes favorably for Q3 EPS and cash flows and offers a short-term opportunity to capitalize on current volatility.

Invitae Busted Business Model Offers A Tactical Opportunity

– Invitae study reports universal genetic testing improves outcomes for patients with breast cancer –  SAN FRANCISCO , Sept. 22, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, released a new study in JAMA Network Open , underscoring the clinical utility of the American Society of Breast Surgeons (ASBrS) guidelines recommending universal genetic testing for patients with breast cancer, and showing universal testing improves patient outcomes.

Clinical Practice Guidelines Recommend Genetic Testing of All Patients with Breast Cancer

Why Invitae Stock Is Jumping Today

– Clinicians agree that evidence supports testing benefits for all –  SAN FRANCISCO , Sept. 15, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, joined other clinical experts in releasing a new commentary in Journal of Clinical Oncology Precision Oncology , underscoring the importance of universal germline testing for all patients with cancer (solid tumors).

Leading Clinical Experts Across the U.S. Unite to Support Universal Genetic Testing for all Patients with Cancer

A day after a nice climb, investors unloaded shares of the medical genetic testing stock.

Why Shares of Invitae Dropped 13% on Tuesday

Invitae Corporation (NYSE:NVTA ) Morgan Stanley 20th Annual Global Healthcare Conference Call September 13, 2022 8:00 AM ET Company Participants Ken Knight - Chief Executive Officer Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning.

Invitae Corporation (NVTA) Morgan Stanley 20th Annual Global Healthcare Conference Transcript

Source: Chepko Danil Vitalevich / Shutterstock.com Invitae (NYSE: NVTA ) stock is in the spotlight today after the company announced a collaboration with Simons Searchlight. Simons is an international research program that focuses on rare genetic neurodevelopmental disorders.

NVTA Stock Alert: Invitae Announces Data-Sharing Partnership With Simons Searchlight

– Researchers will now be able to access rich clinical data on patients with rare neurological disease  –  SAN FRANCISCO , Sept. 12, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a collaboration with Simons Searchlight, an international research program with a goal of accelerating research and improving lives for people with rare genetic neurodevelopmental disorders.

Invitae and Simons Searchlight Partner to Accelerate Research through Data Sharing

Signify Health

2 Cathie Wood Stocks That Soared 60% in August

ARK Innovation ETF

Teladoc

Let's have a look at what Cathie Wood has been buying lately.

Cathie Wood Has Been Buying These Two Stocks Relentlessly

SAN FRANCISCO , Aug. 30, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in the following investor conference: Morgan Stanley 20th Annual Global Healthcare Conference – Fireside chat on Tuesday, September 13, 2022, at 8:00 a.m. Eastern Time in New York City, New York.

Invitae to Present at Upcoming Investor Conference

AMC Entertainment

Carvana

DraftKings

GameStop

Lucid Group

Marathon Digital Holdings

Roundhill Meme ETF

Novavax

Tilray Brands

If you think investing in "meme stocks" is like playing a game of musical chairs, you might be surprised at how quickly the music might stop. The post 9 Key Meme Stocks To Run Out Of Money In Less Than 2 Years appeared first on Investor's Business Daily.

9 Key Meme Stocks To Run Out Of Money In Less Than 2 Years

Invitae (NYSE: NVTA ) stock popped on investors' radars earlier this month thanks to its nearly 277% surge in price on Aug 10. Following its latest earnings report, retail traders jumped into the stock as well.

Invitae Stock Won't Be Tripling Again Any Time Soon

Invitae's long-term prospects look brighter. But we don't know yet how much short interest in the stock has fallen.

Could Another Short Squeeze Be on the Way for Invitae?

The struggling company is pulling out all the stops to attempt a turnaround.

Is There Any Hope for Invitae Stock?

The company's shares recently got a big boost after it reported earnings.

Is Invitae a Buy?

Direct-to-consumer genetic testing via online platforms arouses some skepticism but appears to be a profitable venture in the US anyway. Invitae Corporation could benefit from rising public awareness of direct-to-consumer genetic testing, but the company must streamline activities.

Why Invitae Corporation Could Underperform

Fate Therapeutics

Markforged Holding Corp

Roblox

Cathie Wood's Ark Invest has performed well recently, with shares of her flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT: ARKK ), up more than 15% during the past month. The performance was driven by the release of July's consumer price index (CPI) report.

The 5 Top Stocks Cathie Wood Is Buying Now

Even as Invitae increases its margins and reduces cash burn, eager traders still might have gotten ahead of themselves.

Invitae Stock Soars 277% in a Day: Time to Buy?

After more than doubling overnight, this largely overlooked genetics stock is back in focus.

News for Invitae Stock (NVTA)